Dustri-Verlag, Clinical Nephrology, 02(73), p. 122-130
DOI: 10.5414/cnp73122
Full text: Unavailable
The impact of different therapy modalities on the outcome of Immunoglobulin A glomerulonephritis (IgAGN) in individual patient is not clear. We present preliminary results from the sequential application of renin-angiotensin system (RAS) inhibition and corticosteroids to discriminate the individual effect of both therapies.